IPIX (Innovation Pharmaceuticals) 3-1 Month Momentum %: -70.00% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals 3-1 Month Momentum %?

Innovation Pharmaceuticals IPIX 3-1 Month Momentum % is -70.00% as of Jul. 19, 2026.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-19), Innovation Pharmaceuticals's 3-1 Month Momentum % is -70.00%.

The industry rank for Innovation Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

IPIX's 3-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -13.58 vs IPIX: -70.00

Innovation Pharmaceuticals  (OTCPK:IPIX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Innovation Pharmaceuticals 3-1 Month Momentum % Related Terms

IPIX vs AXIM, RNAZ, APTX: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's 3-1 Month Momentum % falls into.


Innovation Pharmaceuticals  (OTCPK:IPIX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -70.00% mean?
Innovation Pharmaceuticals (IPIX) has a 3-1 Month Momentum % of -70.00% as of Jul. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' 3-1 Month Momentum % too high?
Innovation Pharmaceuticals' current 3-1 Month Momentum % is -70.00%.
How does Innovation Pharmaceuticals' 3-1 Month Momentum % compare to AXIM and RNAZ?
Innovation Pharmaceuticals' 3-1 Month Momentum % of -70.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current 3-1 Month Momentum % is -70.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current 3-1 Month Momentum % of -70.00%. The current 3-1 Month Momentum % is -70.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current 3-1 Month Momentum % is -70.00% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.